AbbVie is taking steps to offset competitive pressures within the pharmaceutical market, involving Sanofi and Johnson & Johnson.

The entities involved

• AbbVie →

  pharmaceutical company

  • AbbVie announced a joint development partnership with IGI, led by Lida Pacaud.Wed 17:17
  • Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Wed 16:42
• Sanofi →

  French pharmaceutical company

  • Sanofi and Abbott face supply limitations in Pakistan, prompting drug inspectors to operate in Lahore.Sun 16:28
  • Abbott Laboratories and Sanofi confirmed the presence of fake vaccines circulating in Pakistan.Sun 16:28
• Johnson & Johnson →

  U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer

  • Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Fri 16:46
  • Zusduri, a product of Urogen Pharma, is gaining market traction against competitors like MSD's Keytruda and Ferring's Adstiladrin.Fri 04:48

Related events

• AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Jun 22
• AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.Jun 17
• AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Jun 8
• AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.Jun 7
• AbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.Jun 7